GRC 54276 has shown tumour cell killing ability in preclinical studies as a single agent and as well in combination with checkpoint inhibitors, making it a high-priority target in immuno-oncology
Highlighted as game changer in drug development & delivery special feature on innovative technologies for improving drug solubility and bioavailability
Through this consortium, Lonza will collaborate with other industry leaders to advance the research and development of inhalation technologies
The plant is scheduled to come on stream in September 2024
Shaker is one of six receiving an individual award, which recognizes people, organizations and products bringing AI to life and applying it to solve real problems
The collaboration will utilize Avatar-Rx, LifeMine’s proprietary genomically-enabled drug discovery platform to access evolutionarily derived lead small molecules
The collaboration leverages Insilico's end-to-end AI-driven Pharma.AI platform to discover novel small molecule drug candidates for multiple targets, along with EQRx's innovative business model to accelerate drug development and patient access to novel medicines at affordable prices
Under the agreement, Lonza will deliver cGMP-standard drug substance for clinical supply
EUROAPI listing on Euronext Paris will occur in H1 2022, despite volatile market conditions
The Mechanisms of Inherited Kidney Disorders (MIKADO) group at the University of Zurich (UZH) and Insilico Medicine will be working together to identify, rank, and annotate novel drug targets to identify potential therapeutics for cystinosis
Subscribe To Our Newsletter & Stay Updated
